Key result
In a patient with hypertrophic cardiomyopathy and preserved ejection fraction, a markedly impaired global longitudinal strain of -6.2% guided the decision to initiate anticoagulation.
Why the study?
The authors intended to demonstrate the clinical utility of global longitudinal strain in patients with hypertrophic cardiomyopathy and preserved ejection fraction.
Case Report (n=1)
No
Global longitudinal strain may serve as a useful prognostic tool to detect subtle left ventricular dysfunction and guide anticoagulation in patients with hypertrophic cardiomyopathy and atrial fibrillation who have preserved ejection fraction.
Answers are grounded in this paper and cite their sources.
GLS may aid evaluation in HCM with preserved EF; hypothesis-generating and requires prospective validation before practice change.
Intending to demonstrate the utility of the global longitudinal strain (GLS) in patients with hypertrophic cardiomyopathy (HCM) and preserved ejection fraction, we describe a case of a 54-year-old female who presented to our emergency department with an acute onset of palpitations and chest pain. The patient was noted to have a new onset of atrial fibrillation. An echocardiogram showed an unimpaired ejection fraction suggesting normal left ventricular systolic function with findings of concentric left ventricular and apical hypertrophy. However, the speckled ultrasound revealed a GLS of -6.2%, suggesting marked impairment of ventricular wall movement. A CHA₂DS₂-VASc score was calculated and yielded a score of 2, indicating a moderate risk for thromboembolism. After a full evaluation of the case, the patient was started on anticoagulation due to her GLS result that suggested stasis within the left ventricle that may lead to a thrombus. Additional advice was to follow up closely for possible automatic implantable cardioverter defibrillator placement. We conclude that GLS is a cheap and easy tool to utilize as an additional prognostic marker for cardiovascular complications, particularly among those who have progression of HCM or start with symptoms such as atrial fibrillation and may have impaired left ventricular systolic function despite a preserved ejection fraction. Thus, we encourage the medical community to utilize and further study this novel technology.
No takes yet. Share an insight, caveat, or question.
Battel et al. (2022) conducted a case report in Hypertrophic cardiomyopathy with preserved left ventricular ejection fraction (n=1). Global longitudinal strain (GLS) measurement was evaluated. In a patient with hypertrophic cardiomyopathy and preserved ejection fraction, a markedly impaired global longitudinal strain of -6.2% guided the decision to initiate anticoagulation.
Synapse has enriched 10 related papers. Consider them for comparative context: